Summary of Chengdu XianDao Conference Call Company Overview - Chengdu XianDao focuses on drug discovery and development, leveraging DEL technology and AI to enhance efficiency in molecular optimization and project success rates [2][15][16]. Key Technologies and Platforms - **Halo Platform**: Integrates DEL technology with AI for high-throughput experiments and rapid molecular optimization, utilizing SAR data [2][15]. - **DMTA High-Throughput Molecular Optimization Platform**: Under development, includes Design, Make, Test, and Analyze phases for continuous molecular optimization [5][6]. - **AI in Drug Discovery**: The company has accumulated over 6,000 protein complex structures, 1.2 trillion compound structures, and nearly 1,000 target experimental data, forming a unique "lead model" for rapid compound testing [2][15]. Clinical Development - **HG146 Pipeline**: Targeting HDAC for solid tumors, currently in Phase II clinical trials with over 20 head and neck cancer patients enrolled. More data expected in Q4 2025 [2][10][26]. - **Second-Generation Small Molecule Inhibitor Project (3,918)**: Focused on AAA and AF diseases, with three preclinical candidates identified. The company seeks partnerships for further development [2][11]. Financial Performance - The biopharmaceutical sector performed well in Q1 2025, with stable year-on-year growth in R&D investment and commercial conversion rates [3][12][14]. - The company is undergoing a merger with a firm specializing in specialty formulations, which is expected to enhance innovation and market reach [4][14]. Collaborations and Market Position - Successful collaboration with Xiantong Bio in nucleic acid drug production, completing the first commercial project. However, the CDMO nucleic acid market is competitive with lower profit margins [4][30]. - The company is exploring international collaborations and has participated in events like the Boston Bio Conference to enhance its global presence [27]. Challenges and Risks - The company acknowledges the risks associated with early-stage projects and the competitive landscape in the CDMO market, particularly in nucleic acid drugs [4][30]. - AI technology has not yet reached widespread industrial application, with varying project outcomes [21]. Future Outlook - Chengdu XianDao aims to continue expanding its capabilities in AI-driven drug discovery and molecular optimization, with a focus on enhancing its commercial offerings and maintaining healthy growth rates [12][15][20].

证券代码：688222 证券简称：成都先导 公告编号：2025-025 成都先导药物开发股份有限公司 股东拉萨经济技术开发区华博医疗器械有限公司 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持计划实施前股东持股的基本情况 | 股东名称 | 拉萨经济技术开发区华博医疗器械有限公司 | | | | | --- | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | | □是 | √否 | | | 直接持股 | 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | | □是 | √否 | | | 其他： | | | | | 持股数量 | 46,770,579股 | | | | | 持股比例 | 11.67% | | | | | 当前持股股份来源 | IPO 前取得：46,770,579股 | | | | 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）大股东因以下事项披露减持计划实施结果： 减持 ...

成都先导公告，股东拉萨经济技术开发区华博医疗器械有限公司在2025年4月18日至2025年6月19日期 间，通过集中竞价交易方式累计减持公司股份200万股，占公司总股本的0.50%。减持价格区间为14.66 元/股至17.79元/股，减持总金额为3175.36万元。减持后，华博器械持有公司股份4477.06万股，占公司 总股本的11.17%。此次减持计划与此前披露的一致，且已实施完毕。 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-024 成都先导药物开发股份有限公司 为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 被担保人：Vernalis (R&D) Limited（以下简称"Vernalis"），系成都先导药 物开发股份有限公司（以下简称"成都先导"或"公司"）的全资子公司。 ? Vernalis 拟继续承租位于英国剑桥郡大阿宾顿格兰塔公园 GP3 的房产 （以 下简称"租赁物业"）作为办公场所用于研发和运营，与 BMR GRANTA PARK PROPCO LIMITED（一家注册于英国马恩岛的公司，以下简称"BMR"）拟签署 《复归租约》。租赁期限自 2026 年 9 月 29 日至 2028 年 3 月 28 日。基本租金为： 自 2027 年 9 月 29 日起，每年 1,023,347.55 英镑（不含增值税）。本次租赁项下， 公司将为 Vernalis 按照《复归租约》的约定支付所有款项及义务提供担保（以下 简称"本次担保 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-024 成都先导药物开发股份有限公司 为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 被担保人：Vernalis (R&D) Limited（以下简称"Vernalis"），系成都先导药 物开发股份有限公司（以下简称"成都先导"或"公司"）的全资子公司。 Vernalis 拟继续承租位于英国剑桥郡大阿宾顿格兰塔公园 GP3 的房产（以 下简称"租赁物业"）作为办公场所用于研发和运营，与 BMR GRANTA PARK PROPCO LIMITED（一家注册于英国马恩岛的公司，以下简称"BMR"）拟签署 《复归租约》。租赁期限自 2026 年 9 月 29 日至 2028 年 3 月 28 日。基本租金为： 2026 年 9 月 29 日至 2027 年 9 月 28 日，每年 993,541.30 英镑（不含增值税）； 自 2027 年 9 月 29 日起，每年 1,023,347.55 英镑（不含增值税）。本次租赁 ...

Core Viewpoint - The company has announced a cash dividend of 0.06 yuan per share, approved at the 2024 annual general meeting held on May 23, 2025 [1][2]. Dividend Distribution Plan - The dividend distribution is based on the total share capital minus shares held in the company's repurchase account, with a total of 399,441,300 shares eligible for distribution [2][4]. - The total cash dividend to be distributed amounts to 23,966,478.00 yuan (including tax) [2]. - The company will not issue bonus shares or capital reserves, and the distribution will only involve cash dividends [2][4]. Implementation Method - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited Shanghai Branch to shareholders registered by the end of the trading day on the record date [5]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date, while those who have not will have their dividends held until they complete the necessary transactions [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.06 yuan per share [8]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the sale of shares [8]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld, resulting in a net distribution of 0.054 yuan per share [9].

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：(86-28) 6739-8000 传真：(86-28) 6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 差异化分红事项的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发股 份有限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下 简称《公司法》）、《中华人民共和国证券法》《上市公司股份回购规则》（以下简 称《回购规则》）、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 （以下简称《回购股份指引》）等相关法律、法规及规范性文件以及《成都先导 药物开发股份有限公司章程》（以下简称《公司章程》）的有关规定，就公司 2024 年度利润分配涉及的差异化分红相关事项（以下简称"本次差异化分红"）出具 本法律意见书。 为出具本法律意见书，本所审查了公司提供的有关文件及其复印件，并取得 公司向本所作出的如下保证：公司已向本所提供了出具本法律意见书所必须的、 真实、完整的原始书 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-023 成都先导药物开发股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否涉及差异化分红送转：是 每股分配比例 3. 差异化分红方案： （1） 差异化分红方案 每股现金红利0.06元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经成都先导药物开发股份有限公司（以下简称"公司"）2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（公 司回购专用证券账户除外）。 根据公司 2024 年年度股东 ...

Group 1 - The core viewpoint of the articles highlights Chengdu Xian Dao's strong market position in the medical service industry, with a high PE ratio compared to industry averages [1][2] - As of March 31, 2025, Chengdu Xian Dao had 16,254 shareholders, an increase of 2,538 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in drug development services related to DEL technology, offering services such as DEL screening, custom DEL libraries, FBDD/SBDD, custom drug development, and chemical synthesis [1] Group 2 - In the first quarter of 2025, the company reported revenue of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.28 million yuan, a year-on-year increase of 102.90%, with a gross margin of 51.87% [2] - Chengdu Xian Dao's rolling PE ratio is 105.26, significantly higher than the industry average of 41.42 and the median of 44.32, ranking 40th in the medical service sector [2] - The company has obtained 138 invention patents and 13 software copyrights, with over 300 additional invention patents currently under application [1]